title: New Drugs 2017, part 1.
authors.affiliation: Daniel A. Hussar, PhD Remington Professor of Pharmacy Philadelphia College of Pharmacy University of the Sciences Philadelphia, Pa.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D017277:Drug Approval; D004358:Drug Therapy / Q000451:nursing; D006801:Humans; D049528:Insulin, Long-Acting / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011108:Polymers / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D014508:Urea / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D049528:Insulin, Long-Acting; D010879:Piperazines; D010880:Piperidines; D011108:Polymers; D011760:Pyrrolidinones; C568789:patiromer; C515492:reslizumab; C571886:insulin degludec; D014508:Urea; C533287:cariprazine; C510793:pimavanserin; C482793:brivaracetam